Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Smith Thomas B | EVP and Chief Medical Officer | Sep 13 '24 | Sale | 36.62 | 9,593 | 351,320 | 53,816 | Sep 17 04:32 PM | | Smith Thomas B | Officer | Sep 13 '24 | Proposed Sale | 36.98 | 373 | 13,794 | | Sep 13 10:39 AM | | Smith Thomas B | Officer | Sep 13 '24 | Proposed Sale | 36.61 | 9,220 | 337,516 | | Sep 13 10:06 AM | | Kuhlmann Shirley R. | EVP and General Counsel | Sep 05 '24 | Sale | 38.30 | 19,248 | 737,198 | 120,161 | Sep 06 05:52 PM | | Kuhlmann Shirley R. | EVP and General Counsel | Sep 06 '24 | Sale | 37.46 | 977 | 36,594 | 119,184 | Sep 06 05:52 PM | | Kuhlmann Shirley R. | Officer | Sep 06 '24 | Proposed Sale | 37.46 | 977 | 36,594 | | Sep 06 11:53 AM | | Kuhlmann Shirley R. | Officer | Sep 05 '24 | Proposed Sale | 38.30 | 19,248 | 737,197 | | Sep 05 04:47 PM | | McFarlane Neil F. | Former Director | Aug 12 '24 | Proposed Sale | 35.21 | 44,365 | 1,562,312 | | Aug 12 02:41 PM | | McFarlane Neil F. | Former Director | Aug 09 '24 | Proposed Sale | 35.20 | 5,000 | 176,007 | | Aug 09 04:34 PM | | Kuhlmann Shirley R. | EVP and General Counsel | Jun 03 '24 | Sale | 32.57 | 25,000 | 814,180 | 139,409 | Jun 05 04:06 PM | | Tupper Colleen | EVP & Chief Financial Officer | May 28 '24 | Sale | 34.21 | 19,710 | 674,368 | 130,845 | May 29 04:29 PM | | Dreyer Scott | EVP & Chief Commercial Officer | May 23 '24 | Option Exercise | 24.03 | 51,209 | 1,230,552 | 190,127 | May 28 04:22 PM | | Dreyer Scott | EVP & Chief Commercial Officer | May 24 '24 | Option Exercise | 24.03 | 23,791 | 571,698 | 162,709 | May 28 04:22 PM | | Dreyer Scott | EVP & Chief Commercial Officer | May 24 '24 | Sale | 33.98 | 56,807 | 1,930,455 | 105,902 | May 28 04:22 PM | | Dreyer Scott | EVP & Chief Commercial Officer | May 23 '24 | Sale | 33.82 | 51,209 | 1,732,093 | 138,918 | May 28 04:22 PM | | BOHLIN GAREN G | Director | May 14 '24 | Option Exercise | 5.73 | 28,985 | 166,084 | 73,760 | May 16 07:20 PM | | BOHLIN GAREN G | Director | May 14 '24 | Sale | 32.30 | 28,985 | 936,311 | 44,775 | May 16 07:20 PM | | Smith Thomas B | EVP and Chief Medical Officer | Feb 29 '24 | Sale | 36.76 | 995 | 36,580 | 63,409 | Mar 04 04:26 PM | | Dreyer Scott | EVP & Chief Commercial Officer | Feb 26 '24 | Sale | 36.43 | 10,000 | 364,270 | 138,918 | Feb 28 04:14 PM | | Dreyer Scott | EVP & Chief Commercial Officer | Jan 16 '24 | Sale | 32.28 | 23,560 | 760,519 | 111,322 | Jan 18 04:19 PM | | Ciaffoni Joseph | President and CEO | Dec 21 '23 | Option Exercise | 21.34 | 4,357 | 92,978 | 279,357 | Dec 22 04:36 PM | | Ciaffoni Joseph | President and CEO | Dec 21 '23 | Sale | 30.38 | 4,357 | 132,377 | 275,000 | Dec 22 04:36 PM | | Ciaffoni Joseph | President and CEO | Dec 18 '23 | Option Exercise | 21.34 | 27,798 | 593,209 | 302,798 | Dec 20 05:51 PM | | Ciaffoni Joseph | President and CEO | Dec 20 '23 | Option Exercise | 21.34 | 26,454 | 564,528 | 301,454 | Dec 20 05:51 PM | | Ciaffoni Joseph | President and CEO | Dec 19 '23 | Option Exercise | 21.34 | 14,516 | 309,771 | 289,516 | Dec 20 05:51 PM | | Ciaffoni Joseph | President and CEO | Dec 18 '23 | Sale | 30.04 | 27,798 | 834,935 | 275,000 | Dec 20 05:51 PM | | Ciaffoni Joseph | President and CEO | Dec 20 '23 | Sale | 30.40 | 26,454 | 804,210 | 275,000 | Dec 20 05:51 PM | | Ciaffoni Joseph | President and CEO | Dec 19 '23 | Sale | 30.03 | 14,516 | 435,942 | 275,000 | Dec 20 05:51 PM |
|
